You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Proton pump inhibitors and gastric cancer: a population-based cohort study
  1. Jigar Patel,
  2. Ivan Berezowski,
  3. Rajesh Naidu Janapala,
  4. Ali Pourmand
  1. The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA
  1. Correspondence to Dr Jigar Patel, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA; jigar.r.patel{at}outlook.com

https://doi.org/10.1136/gutjnl-2021-325385

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the recent article by Seo et al regarding the association of proton pump inhibitors (PPI) and gastric cancer.1 We want to congratulate the authors for their exemplary work as the prevalence of PPI in current clinical practice cannot be overstated. After reviewing the article, we have some comments to share with you.

    As mentioned in the Methods section and also in figure 1, the target cohort was defined as ‘new PPI users’ who were prescribed PPI for more than 30 consecutive days. Although we understood that the subjects underwent 365 days of continuous observation to be classified as new PPI users, we are curious to know if the remote history of PPI use (>365 days ago) was taken into consideration before enrolment into the target cohort. The authors have defined index date as the first day of a new …

    View Full Text

    Footnotes

    • Contributors All authors have made substantial contributions to drafting the manuscript, revising it critically for important intellectual content and final approval of the version to be submitted.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.